Granzyme B -conjugated vascular endothelial growth factor fusion protein (MD Anderson Cancer Center/Clayton Biotechnologies)

N/A

Report date: 2025/03/20 14:59:14

Base Information

Drug NameGranzyme B -conjugated vascular endothelial growth factor fusion protein (MD Anderson Cancer Center/Clayton Biotechnologies)
Drug Alias NameGrB-Fc-VEGFGrB-Fc-VEGF121
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Toxin
Mechanisms of ActionVascular endothelial growth factor receptor modulatorsGranzyme B stimulants
TargetsGranzyme BVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesClayton Foundation For ResearchThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A